Pomegra
Oura IPO Targets $15.6B Valuation on Nasdaq Debut
Why is Oura IPO priced at $15.6 billion?
Oura (OURA) launched its IPO roadshow on Monday at $40–$44 a share, targeting a $15.6B Nasdaq valuation backed by $400M in cornerstone orders from Eli Lilly and Dragoneer.
Key numbers
| IPO Valuation (fully diluted) | $15.6B+42% vs $11B last private round |
|---|---|
| IPO Raise (50M shares at $40–$44) | up to $2.2B~$533M in primary proceeds to Oura |
| Revenue (9M ended Jun 30, 2026) | $1.21B+74% YoY from $697.6M |
| Paid Members | 5.0M+100% YoY from 2.5M |
| Gross Margin (9M FY2026) | 55%+4pp vs 51% prior year |
| Cornerstone Interest | $400MEli Lilly $100M + Dragoneer $300M |
What happened
Oura (OURA) launched its IPO roadshow on Monday at $40–$44 a share, targeting a $15.6B Nasdaq valuation backed by $400M in cornerstone orders from Eli Lilly and Dragoneer. The Finnish smart ring maker is selling 50 million shares — 73% from existing holders — aiming to raise up to $2.2B in total. Revenue for the nine months ended June 30, 2026 hit $1.21B, up 74% year on year, as paid members doubled to 5 million across 56 countries. Oura plans to list on Nasdaq under the ticker OURA during the week of September 28.
Why it matters
Oura is one of the few profitable consumer health companies going public right now, making it a notable test of investor appetite for health-data wearables. Eli Lilly's $100M commitment signals that pharmaceutical companies view health rings as clinical-grade data tools, not just fitness gadgets, which could open a new revenue stream beyond retail consumers. With roughly 80% of global smart ring sales and 85% subscriber retention, Oura enters public life with a dominant market position that rivals like Samsung Galaxy Ring have so far been unable to dent.
Who this affects
- MarketbullishHigh impact
- Nasdaq gains a pure-play consumer health wearables stock.
- CompanybullishHigh impact
- Oura raises ~$533M in primary capital at $15.6B valuation.
- CompetitorsbearishMedium impact
- Garmin and Samsung Galaxy Ring face a better-capitalized rival.
- IndustrybullishMedium impact
- IPO validates smart ring as standalone consumer health category.
Oura vs Garmin, Samsung Galaxy Ring
| OuraOURA:NASDAQ | $15.6B (IPO) | $1.4B | +74% | 55% |
|---|---|---|---|---|
| GarminGRMN:NYSE | $55.9B | $7.9B | +14% | ~57% |
| Samsung Galaxy Ring005930.KS | Samsung: $250B+ | — | — | — |
As of 2026-09-25
How we got here
Oura files S-1 with SEC showing $1.21B revenue and 74% YoY growth.
Oura announces IPO launch; Eli Lilly flags $100M cornerstone interest.
Roadshow begins; 50M shares offered at $40–$44, $15.6B target valuation.
Expected IPO pricing week; Oura to list on Nasdaq as OURA.
What to watch
- IPO pricing and opening-day trade vs $44 top of range on Nasdaq.2026-09-30
- First earnings report revealing FY2026 full-year revenue and guidance.Q4 2026
- Eli Lilly partnership expansion and pharmaceutical use of Oura health data.Q4 2026
Educational content only. Not investment advice.
More briefsAll briefs →
S&P 500 Jumps 2% as Dip-Buyers Return After Worst Week
The S&P 500 (^GSPC) added about $1T as the Nasdaq rose 2.6% and oil slid, easing last week's AI selloff.
Vir Biotechnology Stock Jumps 15% After Phase 3 Trial Win
Vir Biotechnology (VIR) rose as its hepatitis delta drugs passed a Phase 3 test; 44% of patients responded.
Greenfire Stock Jumps 25% After Strathcona Takeover Deal
Greenfire Resources (GFR) is being bought for up to C$2.9B, with a C$11 cash option at a 39% premium.